Document Type

Article

Original Publication Date

2012

Journal/Book/Conference Title

The New England Journal of Medicine

Volume

367

DOI of Original Publication

10.1056/NEJMoa1203517

Comments

Originially Published at http://dx.doi.org/10.1056/NEJMoa1203517

Date of Submission

January 2015

Abstract

BACKGROUND

Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia.

METHODS

We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1:1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37).

RESULTS

The overall survival rate at 2 years in the peripheral-blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P=0.29), with an absolute difference of 5 percentage points (95% CI, −3 to 14). The overall incidence of graft failure in the peripheral-blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P=0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P=0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse.

CONCLUSIONS

We did not detect significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. (Funded by the National Heart, Lung, and Blood Institute–National Cancer Institute and others; ClinicalTrials.gov number, NCT00075816.)

Rights

From The New England Journal of Medicine, Anasetti, C., Logan, B. R., Lee, S.J. et al., Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors, Vol. 367, Page 1487, Copyright © 2012 Massachusetts Medical Society.

Is Part Of

VCU Massey Cancer Center Publications

nejmoa1203517_appendix.pdf (69 kB)
Supplementary Appendix

nejmoa1203517_disclosures.pdf (571 kB)
Disclosure Forms

nejmoa1203517_protocol.pdf (1208 kB)
Protocol

Share

COinS
 
 
 
View graphic versionView graphic version